Growth Hormone testing after stroke (GROWTH)

Not Applicable

• Conditions: Stroke; Human Growth Hormone deficiency; Stroke - Ischaemic; Metabolic and Endocrine - Other endocrine disorders

• Registration Number: ACTRN12615000701527
• Lead Sponsor: John Hunter Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-07-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Ischemic stroke within 5 years.
18 years of age or older
Modified Rankin Score (mRS) of 3 or less
Can speak reasonable English, understand instructions and
be able to complete tests and questionnaires on their own or
with minimal support
Able to give informed consent

Exclusion Criteria

pre-existing depression, dementia or other neuropsychiatric disease

stroke induced by trauma, infection or surgery

current or past drug abuse

known active malignancy, any intracranial tumor, subdural

or epidural hematoma

renal or hepatic impairment

use of benzodiazepines or antiepileptic drugs

patients on immunosuppression or known immunodeficiency state e.g. HIV

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determining the prevalence of human growth hormone deficiency in stroke survivor, defined as a serum HGH concentration of less than 10ng/ml assessed by the arginine/HGHRH test.[One time point, within 5 years of stroke.]

Secondary Outcome Measures

Name	Time	Method
one[None]